

IN THE CLAIMS

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~strike through~~ and additions by underlining)

Listing of Claims:

1-11. (CANCELED)

12. (CURRENTLY AMENDED) The An isolated polypeptide having a length of up to 30 amino acids capable of binding to dendritic cells according to claim 1, wherein said polypeptide comprises a peptide sequence [[is]] selected from the group consisting of PALKT (SEQ ID NO: 6), PSNST (SEQ ID NO: 8), PPNTT (SEQ ID NO: 9), STPPNTT (SEQ ID NO: 17), APSNSTA (SEQ ID NO: 15), and SPALKTV (SEQ ID NO: 16) and wherein said polypeptide is not a full-length naturally-occurring protein.

13-34. (CANCELED)

35. (CURRENTLY AMENDED) The A peptide according to claim 1, wherein X^1 , X^2 , and X^3 ~~may be the same or different, and each represents an amino acid residue~~, selected from the group consisting of PALKT (SEQ ID NO: 6), PSNST (SEQ ID NO: 8), PPNTT (SEQ ID NO: 9), STPPNTT (SEQ ID NO: 17), APSNSTA (SEQ ID NO: 15), and SPALKTV (SEQ ID NO: 16), and wherein the peptide is linked to a polycationic nucleic acid-binding component.

36-41. (CANCELED)

42. (previously presented) The peptide according to claim 35, wherein the peptide is linked to the polycationic nucleic acid-binding component via a spacer element.

43-50. (CANCELED)

51. (CURRENTLY AMENDED) A non-viral transfection mixture comprising:

- (i) a lipid component,
- (ii) a polycationic nucleic acid-binding component, and

(iii) the peptide PALKT (SEQ ID NO: 6) or a peptide with a length up to 30 amino acids comprising the an amino acid sequence

PX¹X²X³T [SEQ ID NO: 1], wherein X¹, X², and X³ may be the same or different, and each represents an amino acid residue selected from the group consisting of PSNST (SEQ ID NO: 8), PPNTT (SEQ ID NO: 9), STPPNTT (SEQ ID NO: 17), APSNSTA (SEQ ID NO: 15), and SPALKTV (SEQ ID NO: 16).

52-53. (CANCELED)

54. (previously presented) The mixture according to claim 51, wherein the lipid component comprises one or more lipids selected from the group consisting of cationic lipids, lipids having membrane destabilising properties, and lipids having fusogenic properties.

55-64. (CANCELED)

65. (CURRENTLY AMENDED) A non-viral transfection complex comprising:

(i) a nucleic acid,

(ii) a lipid component,

(iii) a polycationic nucleic acid-binding component, and

(iv) the peptide PALKT (SEQ ID NO: 6) or a peptide with a length up to 30 amino acids comprising the an amino acid sequence PX¹X²X³T [SEQ ID NO: 1], wherein X¹, X², and X³ may be the same or different, and each represents an amino acid residue selected from the group consisting of PSNST (SEQ ID NO: 8), PPNTT (SEQ ID NO: 9), STPPNTT (SEQ ID NO: 17), APSNSTA (SEQ ID NO: 15), and SPALKTV (SEQ ID NO: 16).

66-75. (CANCELED)

76. (previously presented) A process for the production of a complex according to claim 65, which comprises admixing components (i), (ii), (iii) and (iv) in the following order: lipid component, peptide, polycationic nucleic acid binding component, and nucleic acid.

77-79. (CANCELED)

80. (CURRENTLY AMENDED) A non-viral transfection complex comprising:

(i) a nucleic acid,

(ii) a polycationic nucleic acid-binding component, and

(iii) the peptide PALKT (SEQ ID NO: 6) or a peptide with a length up to 30 amino acids comprising the an amino acid sequence $PX^1X^2X^3T$ [SEQ ID NO: 1] wherein X^1 , X^2 , and X^3 may be the same or different, and each represents an amino acid residue selected from the group consisting of PSNST (SEQ ID NO: 8), PPNTT (SEQ ID NO: 9), STPPNTT (SEQ ID NO: 17), APSNSTA (SEQ ID NO: 15), and SPALKTV (SEQ ID NO: 16).

81-96. (CANCELED)

97. (CURRENTLY AMENDED) A method of transfecting a cell with a nucleic acid, which method comprises contacting the cell *in vitro* or *in vivo* with the transfection complex according to claim 65 or claim 80, ~~or a viral vector according to claim 84.~~

98. (CURRENTLY AMENDED) A ~~pharmaceutical~~ composition comprising the transfection complex according to claim 65 or claim 80 ~~or a viral vector according to claim 84~~, said composition being in admixture or conjunction with a pharmaceutically suitable carrier.

99. (CURRENTLY AMENDED) A method for expressing a gene ~~the treatment or prophylaxis of a condition caused in a human or in a non-human animal~~ [[by]] with a defect and/or a deficiency in a gene, which method comprises administering the transfection complex according to claim 65 or claim 80 ~~or viral vector according to claim 84~~ to the human or to the non-human animal.

100. (CURRENTLY AMENDED) A method for inducing an immune response in ~~the therapeutic or prophylactic immunisation of a human or~~ [[of]] a non-human animal, which method comprises administering the transfection complex according to claim 65 or claim 80 ~~or the viral vector according to claim 84~~ to the human or to the non-human animal.

101. (CURRENTLY AMENDED) A method of inhibiting the expression of a gene ~~anti-sense therapy~~, which method comprises administering the transfection complex according to claim 65 or claim 80 ~~or the viral vector according to claim 84~~ to a human or to a non-human animal.

102-104. (CANCELED)

105. (CURRENTLY AMENDED) A kit comprising:

- (i) a nucleic acid,
- (ii) a polycationic nucleic acid-binding component, and
- (iii) the peptide PALKT (SEQ ID NO: 6) or a peptide with a length up to 30 amino acids comprising [[the]] an amino acid sequence $PX^1X^2X^3T$ [SEQ ID NO: 1], wherein X^1 , X^2 , and X^3 may be the same or different, and each represents an amino acid residue selected from the group consisting of PSNST (SEQ ID NO: 8), PPNTT (SEQ ID NO: 9), STPPNTT (SEQ ID NO: 17), APSNSTA (SEQ ID NO: 15), and SPALKTV (SEQ ID NO: 16), and, optionally,
- (iv) a lipid component.

106-110. (CANCELED)

111. (previously presented) The peptide according to claim 12, wherein the peptide consists of the amino acid sequence APSNSTA [SEQ ID NO: 15].